Proportion of long-term event-free survivors and lifetime of adult patients not cured after a standard acute lymphoblastic leukemia therapeutic program

Adult acute lymphoblastic leukemia-94 trial

Authors

  • Quoc-Hung Le MD,

    1. Service d'Hematologie, Hopital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
    2. Service de Biostatistique, Hospices Civils de Lyon, Lyon, France
    3. Uniteé Mixte de Recherche 5558 Equipe Biostatistique-Sante, Centre National de Recherche Scientifique, Villeurbanne, France
    Search for more papers by this author
  • Xavier Thomas MD, PhD,

    Corresponding author
    1. Service d'Hematologie, Hopital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
    • Service d'Hematologie, Hopital Edouard Herriot, 69437 Lyon Cedex 03, France
    Search for more papers by this author
    • Fax: (011) 33-472117404

  • Reneé Ecochard MD, PhD,

    1. Service de Biostatistique, Hospices Civils de Lyon, Lyon, France
    2. Uniteé Mixte de Recherche 5558 Equipe Biostatistique-Sante, Centre National de Recherche Scientifique, Villeurbanne, France
    Search for more papers by this author
  • Jean Iwaz PhD,

    1. Service de Biostatistique, Hospices Civils de Lyon, Lyon, France
    2. Uniteé Mixte de Recherche 5558 Equipe Biostatistique-Sante, Centre National de Recherche Scientifique, Villeurbanne, France
    Search for more papers by this author
  • Veéronique Lheéritier CRA,

    1. Service d'Hematologie, Hopital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
    Search for more papers by this author
  • Mauricette Michallet MD, PhD,

    1. Service d'Hematologie, Hopital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
    Search for more papers by this author
  • Denis Fiere MD

    1. Service d'Hematologie, Hopital Edouard Herriot, Hospices Civils de Lyon, Lyon, France
    Search for more papers by this author

Abstract

BACKGROUND.

In adult acute lymphoblastic leukemia, treatment results generally are expressed in terms of overall survival or disease-free survival at 3 years. In this investigation, the authors attempted to express the results in terms of the proportion of long-term disease-free survivors and in terms of lifetime in patients who developed recurrent disease or died.

METHODS.

Univariate and multivariate analyses were used to assess the influence of different covariates on the 2 result criteria in 922 participants in the Adult Acute Lymphoblastic Leukemia-94 multicenter trial.

RESULTS.

The proportion of long-term survivors was 21.5% (95% confidence interval [95% CI], 18.1–25.4%) and was higher in women than in men. The proportion decreased with increasing age, white blood cell count, and lactate dehydrogenase level. The lowest proportion was observed in patients ages 44 years to 55 years (11.4%; 95% CI, 7–17.9%) and in patients with the t(9;22) BCR-ABL karyotype (13.4%; 95% CI, 8.8–19.8%), and the highest proportion was observed in patients with the t(4;11) MLL-AF4 karyotype (31.3%; 95% CI, 18.2–48.3%). The mean expected lifetime of patients who were not cured was 11.4 months (95% CI, 9.1–14.1 months). It was longer in men than in women and was shorter with increasing age, performance status, hemoglobin level, and white blood cell count.

CONCLUSIONS.

The results of this study highlighted and specified the importance of some classic prognostic factors in patients with acute lymphoblastic leukemia. Cancer 2007. © 2007 American Cancer Society.

Ancillary